Bupivacaine HCl for Pain, Postoperative

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Pain, Postoperative
Bupivacaine Hydrochloride - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing if adding bupivacaine HCl injections to standard care after skin surgery can help improve pain control for patients.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Pain, Postoperative

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 3 Days Post-Surgery

3 Days Post-Surgery
Reported opioid and non-opioid pain medications taken

Trial Safety

Safety Progress

1 of 3

Other trials for Pain, Postoperative

Trial Design

2 Treatment Groups

Bupivacaine HCl
1 of 2
Saline
1 of 2
Active Control
Non-Treatment Group

100 Total Participants · 2 Treatment Groups

Primary Treatment: Bupivacaine HCl · Has Placebo Group · Phase 1

Bupivacaine HCl
Drug
ActiveComparator Group · 1 Intervention: Bupivacaine Hydrochloride · Intervention Types: Drug
Saline
Drug
PlaceboComparator Group · 1 Intervention: Saline · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 days post-surgery

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,432 Previous Clinical Trials
769,437 Total Patients Enrolled
12 Trials studying Pain, Postoperative
628 Patients Enrolled for Pain, Postoperative
Murad Alam, MDPrincipal InvestigatorNorthwestern University
69 Previous Clinical Trials
2,579 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 31st, 2021

Last Reviewed: October 16th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.